Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (386) | (325) |
| Net cash used in operating activities | (29,893) | (23,355) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (102) | (187) |
| Maturities of marketable securities | 55,000 | 30,000 |
| Net cash provided by investing activities | 54,898 | 29,813 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 56 | — |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s capex?
- Aura Biosciences, Inc. (AURA) reported capex of $102K in Q1 2026.
- How has Aura Biosciences, Inc.'s capex changed year-over-year?
- Aura Biosciences, Inc.'s capex decreased by 45.5% year-over-year, from $187K to $102K.
- What is the long-term trend for Aura Biosciences, Inc.'s capex?
- Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s capex has grown at a -32.3% compound annual growth rate (CAGR), from $2.13M to $447K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Aura Biosciences, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude